Indication assessment · §3
Knee osteoarthritis with obesity — trial records
Trial records in the Institute's register bearing on knee osteoarthritis with obesity.
§3Trials in this indication
11 trial records in the Institute's register bear on this indication, of which 3 are published trials.
Table 2. Trial records bearing on knee osteoarthritis with obesity.
| Record | Compound | Phase | Design | Randomised | Year |
|---|---|---|---|---|---|
| SURMOUNT-KOA | Tirzepatide | Phase 3 | Randomised, double-blind, placebo-controlled | — | 2025 |
| TRIUMPH-4 | Retatrutide | Phase 3 | Randomised, double-blind, placebo-controlled | — | — |
| AOD-OA-PH2 | AOD-9604 | Phase 2 | Randomised, double-blind, placebo-controlled | — | 2015 |
| SURMOUNT-KOA-REGIONAL-JPprogramme record | Tirzepatide | Phase 3 | Randomised, double-blind, placebo-controlled | — | 2025 |
| TRIUMPH-4-BODY-COMPprogramme record | Retatrutide | Phase 3 | Randomised, double-blind, placebo-controlled | — | — |
| AOD-OA-PH2-PKprogramme record | AOD-9604 | Phase 1 | Phase 1 ascending dose | — | 2015 |
| SURMOUNT-KOA-BODY-COMPprogramme record | Tirzepatide | Phase 3 | Randomised, double-blind, placebo-controlled | — | 2025 |
| TRIUMPH-4-REGIONAL-JPprogramme record | Retatrutide | Phase 3 | Randomised, double-blind, placebo-controlled | — | — |
| AOD-OA-PH2-RENAL-IMPprogramme record | AOD-9604 | Phase 1 | Phase 1 ascending dose | — | 2015 |
| AOD-OA-PH2-HEPATIC-IMPprogramme record | AOD-9604 | Phase 1 | Phase 1 ascending dose | — | 2015 |
| AOD-OA-PH2-BODY-COMPprogramme record | AOD-9604 | Phase 2 | Randomised, double-blind, placebo-controlled | — | 2015 |
| This facet in the trial register. | |||||
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Heffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and β3-AR knock-out mice. Endocrinology 2001;142(12):5182–5189. doi:10.1210/endo.142.12.8522 · PMID 11713213
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.
Compound Evidence Institute · CEI-IN-15/3 · https://compoundevidence.com/indications/knee-oa/trials/ · retrieved 30 July 2026